SAB Biotherapeutics (SABS) Stock Forecast, Price Target & Predictions
SABS Stock Forecast
SAB Biotherapeutics stock forecast is as follows: an average price target of $5.67 (represents a 85.29% upside from SABS’s last price of $3.06) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
SABS Price Target
SABS Analyst Ratings
Buy
SAB Biotherapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jun 07, 2024 | Kumaraguru Raja | Loop Capital Markets | $8.00 | $2.84 | 181.69% | 161.44% |
Apr 02, 2024 | Edward White | H.C. Wainwright | $6.00 | $4.29 | 39.86% | 96.08% |
Aug 11, 2022 | - | Chardan Capital | $3.00 | $1.12 | 167.86% | -1.96% |
10
SAB Biotherapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 2 |
Avg Price Target | - | - | $7.00 |
Last Closing Price | $3.06 | $3.06 | $3.06 |
Upside/Downside | -100.00% | -100.00% | 128.76% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 09, 2024 | Craig-Hallum | - | Buy | Initialise |
Aug 27, 2024 | Oppenheimer | - | Outperform | Initialise |
Jun 07, 2024 | Brookline Capital | - | Buy | Initialise |
Apr 02, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Aug 11, 2022 | Chardan Capital | Buy | Buy | Hold |
May 13, 2022 | Chardan Capital | Buy | Buy | Hold |
10
SAB Biotherapeutics Financial Forecast
SAB Biotherapeutics Revenue Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | $1.27M | $85.52K | $581.10K | $2.16M | $3.59M | $6.35M | $11.80M | $60.88M | - |
Avg Forecast | $500.00K | $500.00K | $500.00K | $500.00K | $333.33K | $333.33K | $333.33K | $333.33K | $120.00K | $120.00K | $263.14K | $11.97K | $400.00K | $2.54M | $5.90M | $6.85M | $10.80M | $11.47M | $16.90M | $14.40M |
High Forecast | $500.00K | $500.00K | $500.00K | $500.00K | $333.33K | $333.33K | $333.33K | $333.33K | $120.00K | $120.00K | $263.14K | $11.98K | $400.00K | $2.54M | $5.90M | $6.85M | $10.80M | $11.47M | $16.90M | $17.28M |
Low Forecast | $500.00K | $500.00K | $500.00K | $500.00K | $333.33K | $333.33K | $333.33K | $333.33K | $120.00K | $120.00K | $263.14K | $11.95K | $400.00K | $2.54M | $5.90M | $6.85M | $10.80M | $11.47M | $16.90M | $11.52M |
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 4 | 7 | 5 | 11 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 105.91% | 0.21% | 0.23% | 0.37% | 0.52% | 0.59% | 1.03% | 3.60% | - |
Forecast
SAB Biotherapeutics EBITDA Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 4 | 7 | 5 | 11 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-4.23M | $-6.48M | $-6.42M | $-7.80M | $-6.88M | $-5.75M | $-6.02M | $-11.52M | $-337.35K |
Avg Forecast | $-249.96K | $-249.96K | $-249.96K | $-249.96K | $-166.64K | $-166.64K | $-166.64K | $-166.64K | $-59.99K | $-59.99K | $-147.87K | $-5.98K | $-199.97K | $-1.27M | $-2.95M | $-3.85M | $-6.07M | $-6.44M | $-9.50M | $-539.75K |
High Forecast | $-249.96K | $-249.96K | $-249.96K | $-249.96K | $-166.64K | $-166.64K | $-166.64K | $-166.64K | $-59.99K | $-59.99K | $-147.87K | $-5.97K | $-199.97K | $-1.27M | $-2.95M | $-3.85M | $-6.07M | $-6.44M | $-9.50M | $-431.80K |
Low Forecast | $-249.96K | $-249.96K | $-249.96K | $-249.96K | $-166.64K | $-166.64K | $-166.64K | $-166.64K | $-59.99K | $-59.99K | $-147.87K | $-5.99K | $-199.97K | $-1.27M | $-2.95M | $-3.85M | $-6.07M | $-6.44M | $-9.50M | $-647.70K |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 706.44% | 32.39% | 5.06% | 2.64% | 1.79% | 0.95% | 0.93% | 1.21% | 0.63% |
Forecast
SAB Biotherapeutics Net Income Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 4 | 7 | 5 | 11 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | $-5.10M | $-6.88M | $-7.40M | $-7.87M | $-6.34M | $-4.78M | $985.86K | $-17.88M | $-326.11K |
Avg Forecast | $-8.43M | $-8.15M | $-7.87M | $-7.59M | $-6.27M | $-6.23M | $-6.11M | $-8.27M | $-10.78M | $-10.24M | $-10.61M | $-10.80M | $-12.96M | $-10.49M | $-9.03M | $-13.27M | $-12.03M | $-13.27M | $-8.02M | $-529.33K |
High Forecast | $-8.43M | $-8.15M | $-7.87M | $-7.59M | $-6.27M | $-6.23M | $-6.11M | $-8.27M | $-9.65M | $-10.24M | $-10.61M | $-10.80M | $-12.96M | $-10.49M | $-9.03M | $-13.27M | $-12.03M | $-13.27M | $-8.02M | $-423.46K |
Low Forecast | $-8.43M | $-8.15M | $-7.87M | $-7.59M | $-6.27M | $-6.23M | $-6.11M | $-8.27M | $-12.18M | $-10.24M | $-10.61M | $-10.80M | $-12.96M | $-10.49M | $-9.03M | $-13.27M | $-12.03M | $-13.27M | $-8.02M | $-635.19K |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.47% | 0.53% | 0.70% | 0.87% | 0.48% | 0.40% | -0.07% | 2.23% | 0.62% |
Forecast
SAB Biotherapeutics SG&A Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 4 | 7 | 5 | 11 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | $2.57M | $2.90M | $3.45M | $2.88M | $4.04M | $4.31M | $5.19M | $17.09M | - |
Avg Forecast | $1.12M | $1.12M | $1.12M | $1.12M | $749.02K | $749.02K | $749.02K | $749.02K | $269.65K | $269.65K | $591.29K | $26.89K | $898.83K | $5.71M | $13.26M | $15.39M | $24.27M | $25.77M | $37.97M | $32.36M |
High Forecast | $1.12M | $1.12M | $1.12M | $1.12M | $749.02K | $749.02K | $749.02K | $749.02K | $269.65K | $269.65K | $591.29K | $26.93K | $898.83K | $5.71M | $13.26M | $15.39M | $24.27M | $25.77M | $37.97M | $38.83M |
Low Forecast | $1.12M | $1.12M | $1.12M | $1.12M | $749.02K | $749.02K | $749.02K | $749.02K | $269.65K | $269.65K | $591.29K | $26.85K | $898.83K | $5.71M | $13.26M | $15.39M | $24.27M | $25.77M | $37.97M | $25.89M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 95.60% | 3.23% | 0.60% | 0.22% | 0.26% | 0.18% | 0.20% | 0.45% | - |
Forecast
SAB Biotherapeutics EPS Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 4 | 7 | 5 | 11 |
EPS | - | - | - | - | - | - | - | - | - | - | - | $-0.10 | $-0.14 | $-0.15 | $-0.18 | $-0.15 | $-0.11 | $0.02 | $-0.41 | $-0.09 |
Avg Forecast | $-0.91 | $-0.88 | $-0.85 | $-0.82 | $-0.68 | $-0.67 | $-0.66 | $-0.89 | $-1.16 | $-1.11 | $-1.15 | $-1.17 | $-1.40 | $-1.13 | $-0.97 | $-1.43 | $-1.30 | $-1.43 | $-0.87 | $1.25 |
High Forecast | $-0.91 | $-0.88 | $-0.85 | $-0.82 | $-0.68 | $-0.67 | $-0.66 | $-0.89 | $-1.04 | $-1.11 | $-1.15 | $-1.17 | $-1.40 | $-1.13 | $-0.97 | $-1.43 | $-1.30 | $-1.43 | $-0.87 | $1.25 |
Low Forecast | $-0.91 | $-0.88 | $-0.85 | $-0.82 | $-0.68 | $-0.67 | $-0.66 | $-0.89 | $-1.32 | $-1.11 | $-1.15 | $-1.17 | $-1.40 | $-1.13 | $-0.97 | $-1.43 | $-1.30 | $-1.43 | $-0.87 | $1.25 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.08% | 0.10% | 0.13% | 0.18% | 0.10% | 0.08% | -0.01% | 0.47% | -0.08% |
Forecast
SAB Biotherapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
PCSA | Processa Pharmaceuticals | $0.91 | $9.00 | 889.01% | Buy |
ANEB | Anebulo Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
CVKD | Cadrenal Therapeutics | $14.50 | $32.00 | 120.69% | Buy |
SABS | SAB Biotherapeutics | $3.06 | $5.67 | 85.29% | Buy |
MNPR | Monopar Therapeutics | $19.00 | $29.50 | 55.26% | Buy |
THRD | Third Harmonic Bio | $11.62 | $16.15 | 38.98% | Buy |